Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Text message nudge boosts mammogram attendance in norway

NCT ID NCT07355569

Knowledge-focused Sponsor: Norwegian Institute of Public Health Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether sending a simple SMS reminder a few days before a scheduled mammogram could increase attendance in Norway's national breast cancer screening program. Over 133,000 women aged 50-69 were randomly assigned to receive a reminder either 2 or 3 days before their appointment, or no reminder at all. The goal was to see if a low-cost text message could improve screening rates and help catch cancer earlier.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SMS notification
What this could lead to
If successful, this could show that simple text reminders boost screening attendance, potentially saving lives through earlier cancer detection.
What could go wrong
This is a completed study, so results are known. The benefit depends on whether SMS reminders actually increase attendance in real-world settings, and it may not apply to other populations or screening programs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

133,770 people

The number who actually took part.

Started

Jan 2025

Finished

Oct 2025

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 71 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * women invited to BreastScreen Norway residing in the South-Eastern, Central, and Northern Norway Regional Health Authorities Exclusion Criteria: * no

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Attendance are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Attendance Breast cancer screening

Contacts and locations

Locations

  • Norwegian Institute of Public Health

    Oslo, Oslo, 222, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.